BridgeBio to Participate in the J.P. Morgan Healthcare Conference
BridgeBio (Nasdaq: BBIO) said co-founder and CEO Neil Kumar, Ph.D. will present at the 44th Annual J.P.
Rhea-AI Summary
BridgeBio (Nasdaq: BBIO) said co-founder and CEO Neil Kumar, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 7:30 am PT. Investors may watch a live webcast via the company’s Investors > Events & Presentations page at http://investor.bridgebio.com. A replay will be available on the company website for 30 days after the presentation.
Details
News Market Reaction – BBIO
On Jan 5, the day this news came out, BBIO closed 6.15% below the previous close.
Data tracked by StockTitan Argus for the Jan 5 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation time
- 7:30 am PT
- January 12 conference presentation
- Webcast replay window
- 30 days
- Replay available after the event
Historical Context
-
New-hire inducement RSU grants totaling 29,472 shares with scheduled vesting.
-
Participation in two December healthcare investor fireside chats with webcasts.
-
Inducement equity awards totaling 34,199 RSUs for 12 new employees.
-
Planned presentations at two November 2025 global healthcare investor conferences.
-
ATTRibute-CM acoramidis data with mortality, hospitalization, and biomarker benefits at AHA.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12 at 7:30 am PT.
To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
BridgeBio Media Contact: Bubba Murarka, Executive Vice President contact@bridgebio.com (650)-789-8220 BridgeBio Investor Contact: Chinmay Shukla, Senior Vice President, Strategic Finance ir@bridgebio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.